Two months after Sanofi completed construction in France of its innovative Modulus vaccine and biologics plant—which can be ...
Sac-TMT, also known as SKB264 or MK-2870, represents the first asset in Kelun’s multitarget, multibillion-dollar ADC ...
Before Exelexis’ Cabometyx can pass muster with the FDA in its hopeful neuroendocrine tumors indication next April, it will ...
On a routine basis in recent years, headlines about layoffs in the biopharma industry have surfaced as companies large and ...
Once a controversial European depression treatment that never made it to the U.S. | The treatment, which was once a Pfizer ...